Home » Stocks » IDXG

Interpace Biosciences, Inc. (IDXG)

Stock Price: $8.75 USD -0.10 (-1.13%)
Updated Jul 30, 2021 2:55 PM EDT - Market closed
Market Cap 35.99M
Revenue (ttm) 33.17M
Net Income (ttm) -24.16M
Shares Out 4.09M
EPS (ttm) -5.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $8.75
Previous Close $8.85
Change ($) -0.10
Change (%) -1.13%
Day's Open 8.75
Day's Range 8.75 - 9.10
Day's Volume 4,956
52-Week Range 2.57 - 10.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma...

1 month ago - Zacks Investment Research

Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer a...

2 months ago - GlobeNewsWire

PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 an...

2 months ago - GlobeNewsWire

Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally pr...

3 months ago - GlobeNewsWire

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in ...

3 months ago - GlobeNewsWire

Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agre...

3 months ago - GlobeNewsWire

PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 20...

4 months ago - GlobeNewsWire

Part of Company's Site Consolidation and Cost Savings Measures

4 months ago - GlobeNewsWire

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

5 months ago - GlobeNewsWire

PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announ...

5 months ago - GlobeNewsWire

PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February ...

5 months ago - GlobeNewsWire

PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders:

5 months ago - GlobeNewsWire

PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has app...

5 months ago - GlobeNewsWire

Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, an...

6 months ago - GlobeNewsWire

In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer

6 months ago - GlobeNewsWire

PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after ...

6 months ago - GlobeNewsWire

Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET

6 months ago - GlobeNewsWire

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 202...

8 months ago - GlobeNewsWire

PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff (th...

8 months ago - GlobeNewsWire

 Study Demonstrates Superior Performance of ThyGeNEXT ® and ThyraMIR ® vs. Other Molecular Tests

9 months ago - GlobeNewsWire

Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million

9 months ago - GlobeNewsWire

Interpace Biosciences (IDXG) news for Wednesday includes a positive audit committee result giving IDXG stock a much-needed boost. The post Interpace Biosciences News: Why IDXG Stock Is Soaring 48% Today...

9 months ago - InvestorPlace

PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has complet...

9 months ago - GlobeNewsWire

 Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting

1 year ago - GlobeNewsWire

Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

First Quarter Net Revenue Improved Over 53% to $9.2 Million

1 year ago - GlobeNewsWire

In-Network Access for More Than 3 Million Members

1 year ago - GlobeNewsWire

Conference Call and Webcast Wednesday April 22, 2020 5:00 pm ET

1 year ago - GlobeNewsWire

Interpace Biosciences (NASDAQ: IDXG) provides complex molecular analysis for the early diagnosis and treatment of cancer.

1 year ago - Benzinga

Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue ...

1 year ago - GlobeNewsWire

In-Network Access for More Than 3 Million Members

1 year ago - GlobeNewsWire

Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s Thy...

1 year ago - GlobeNewsWire

Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for...

1 year ago - GlobeNewsWire

PARSIPPANY, NJ, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Ron Rocca, Pre...

1 year ago - GlobeNewsWire

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2...

Other stocks mentioned: CGEN, GLUU, GME, GRPN, MEET, OGI, RTIX ...
1 year ago - 24/7 Wall Street

Underappreciated Drivers, Bargain Valuation, And Cash Infusion Set Interpace Up For Substantial Upside

1 year ago - Seeking Alpha

Underappreciated Drivers, Bargain Valuation & Cash Infusion Set Interpace Up For Substantial Upside

1 year ago - Seeking Alpha

Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, In...

1 year ago - GlobeNewsWire

Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage det...

1 year ago - GlobeNewsWire

Further Strengthens Business Development Team with Key Hire

1 year ago - GlobeNewsWire

PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharm...

1 year ago - GlobeNewsWire

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date

1 year ago - GlobeNewsWire

Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR®

1 year ago - GlobeNewsWire

PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual ...

1 year ago - GlobeNewsWire

Interpace hosts 2nd Annual Fellow Programs

1 year ago - GlobeNewsWire

PARSIPPANY, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capit...

1 year ago - GlobeNewsWire

PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silico...

1 year ago - GlobeNewsWire

In-Network Access for Thyroid Assays for More than 5 Million Members

1 year ago - GlobeNewsWire

About IDXG

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-ex... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 20, 1998
CEO
Nancy Lurker
Employees
152
Stock Exchange
OTCMKTS
Ticker Symbol
IDXG
Full Company Profile

Financial Performance

In 2020, IDXG's revenue was $32.40 million, an increase of 33.77% compared to the previous year's $24.22 million. Losses were -$26.45 million, -1.08% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for IDXG stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 2.86% from the latest price.

Price Target
$9.00
(2.86% upside)
Analyst Consensus: Buy